Skip to content

Trial Summary

The aim of this study is to evaluate the the PET imaging agent, O-(2-[18F]-fluoroethyl)L-tyrosine (FET) to definitively establish the role of FET-PET in the management of brain cancer (Glioblastoma).



ACTRN/NCT /ethics:


Scientific title:

Prospective, multicentre trial evaluating O-(2-[18F]-fluoroethyl)-L-tyrosine Positron Emission Tomography in Glioblastoma (FET-PET in Glioblastoma)

Sponsor / Cooperative group:

Trans Tasman Radiation Oncology Group (TROG)

Trial & Patient Characteristics

Cancer TypeBrain & central nervous system
Trial TypeTreatment
PhaseAll phases
Age Range18 years and older
Tumour Stream Glioblastoma
Cancer StageAll stages
Anticipated Start Date2020-02-03
Anticipated End Date2023-05-01

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Phone08 7074 2342
Principal InvestigatorAssociate Professor Peter Gorayski
Recruitment StatusRecruiting